経口経粘膜薬の世界市場レポート 2025年

経口経粘膜薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.3%で、620億3,000万米ドルに成長します。予測期間の成長は、個別化医療の進展、新規ドラッグデリバリーシステムに関する研究の増加、高齢者人口の拡大、口腔の健康に対する意識の高まり、非侵襲的治療に対する需要の高まり、規制状況の進化などに起因すると考えられます。予測期間における主な動向には、新規製剤の採用、個別化医療アプローチ、遠隔医療の進展、デジタルヘルス技術の統合、医薬品における技術革新などがあります。

経口経粘膜製剤市場の成長は、パーキンソン病の罹患率の増加が牽引すると予想されます。パーキンソン病は、脳内のドーパミン産生細胞の減少による震え、こわばり、運動障害を特徴とする進行性の神経疾患です。パーキンソン病の有病率上昇の要因としては、人口の高齢化、環境汚染物質、遺伝的脆弱性、発見率を高める診断能力の向上などが挙げられます。経口経粘膜薬は、迅速な薬物吸収を可能にし、消化器系の課題を克服することで、迅速な緩和、アドヒアランスの向上、運動合併症の減少をもたらし、パーキンソン病治療をサポートする上で重要な役割を果たします。例えば、Parkinson's Foundationの報告によると、米国では現在約100万人がパーキンソン病を患っており、2030年には120万人に増加すると予想されています。この動向は、パーキンソン病の罹患率の増加が経口経粘膜製剤市場の拡大に拍車をかけていることを裏付けています。

経口経粘膜薬市場の主要企業は、薬物送達効率を高め、患者の利便性を向上させ、治療成果を最適化するために、舌下ビタミンスプレーなどの革新的な薬物送達ソリューションの開発に注力しています。舌下ビタミンスプレーは、ビタミンを舌の下の粘膜から直接血流に送り込むドラッグデリバリーシステムで、消化管と肝臓の代謝をバイパスして迅速かつ効率的に吸収させる。例えば、ヴェステージ・マーケティングは2022年10月、従来の経口法に比べ3～10倍の吸収を実現し、迅速な吸収と結果をもたらす舌下ビタミンスプレー「Absorvit」を発表しました。B12、C、D、マルチビタミンを含む必須ビタミンのアップグレードされた形態と正確な用量が含まれており、健康増進のための最適な栄養素供給を保証します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界経口経粘膜薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の経口経粘膜薬市場：成長率分析
• 世界の経口経粘膜薬市場の実績：規模と成長, 2019-2024
• 世界の経口経粘膜薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界経口経粘膜薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口経粘膜薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• フィルム
• 液体とスプレー
• その他の製品タイプ
• 世界の経口経粘膜薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オピオイド依存症
• 吐き気と嘔吐
• 勃起不全
• 神経疾患
• その他の適応症
• 世界の経口経粘膜薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 舌下粘膜
• 頬粘膜
• その他の投与経路
• 世界の経口経粘膜薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の経口経粘膜薬市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バッカル錠
• 舌下錠
• 発泡錠
• 世界の経口経粘膜薬市場、映画の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 口腔フィルム
• 舌下フィルム
• 粘膜付着性フィルム
• 世界の経口経粘膜薬市場、液体とスプレーの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 舌下液
• 経口スプレー（鎮痛剤、睡眠補助剤）
• 粘膜ゲル
• 世界の経口経粘膜薬市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロゼンジ
• パスティル
• チューインガム

第7章 地域別・国別分析

• 世界の経口経粘膜薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口経粘膜薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口経粘膜薬市場：競合情勢
• 経口経粘膜薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly & Company Ltd.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Actavis Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Endo Pharmaceuticals Inc.
• Lupin Limited
• Zydus Lifesciences Limited
• Mallinckrodt Pharmaceuticals Plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口経粘膜薬市場2029：新たな機会を提供する国
• 経口経粘膜薬市場2029：新たな機会を提供するセグメント
• 経口経粘膜薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oral transmucosal drugs are medications designed to be absorbed through the mucous membranes in the mouth, offering rapid effects while bypassing initial metabolism in the liver and gastrointestinal tract. These drugs are commonly utilized for conditions requiring swift relief, such as pain management, and for patients facing challenges with swallowing pills.

The primary types of oral transmucosal drugs include tablets, films, liquid formulations, sprays, and other related forms. Tablets within this category are solid dosage forms intended for administration through the mucous membranes in the mouth. They are indicated for various conditions such as opioid dependence, nausea and vomiting, erectile dysfunction, neurological disorders, and others, typically administered via the sublingual or buccal mucosa routes and distributed through hospital pharmacies, retail pharmacies, and online platforms.

The oral transmucosal drugs market research report is one of a series of new reports from The Business Research Company that provides oral transmucosal drugs market statistics, including oral transmucosal drugs industry global market size, regional shares, competitors with oral transmucosal drugs market share, detailed oral transmucosal drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the oral transmucosal drugs industry. This oral transmucosal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral transmucosal drugs market size has grown strongly in recent years. It will grow from $39.7 billion in 2024 to $43.53 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to advancements in diagnostic capabilities, aging demographics, environmental pollutants, genetic susceptibilities, enhanced detection rates, faster relief facilitated by fast drug absorption, and better adherence.

The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $62.03 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in personalized medicine, increasing research on novel drug delivery systems, expanding geriatric population, growing awareness of oral health, rising demand for non-invasive treatments, and evolving regulatory landscapes. Major trends in the forecast period include adoption of novel formulations, personalized medicine approaches, telehealth advancements, integration of digital health technologies and technological innovations in pharmaceuticals.

The growth of the oral transmucosal drug market is expected to be driven by the increasing incidence of Parkinson's disease. Parkinson's disease is a progressive neurological disorder characterized by tremors, stiffness, and movement difficulties due to a decline in dopamine-producing cells in the brain. Factors contributing to the rising prevalence of Parkinson's disease include aging populations, environmental pollutants, genetic vulnerabilities, and improved diagnostic capabilities that enhance detection rates. Oral transmucosal drugs play a crucial role in supporting Parkinson's disease treatment by enabling rapid drug absorption and overcoming digestive challenges, resulting in quicker relief, improved adherence, and potentially fewer motor complications. For example, the Parkinson's Foundation reported that approximately 1 million individuals in the United States currently have Parkinson's disease, expected to rise to 1.2 million by 2030. This trend underscores how the increasing incidence of Parkinson's disease is fueling the expansion of the oral transmucosal drug market.

Leading companies in the oral transmucosal drug market are focused on developing innovative drug delivery solutions, such as sublingual vitamin sprays, to enhance drug delivery efficiency, enhance patient convenience, and optimize therapeutic outcomes. A sublingual vitamin spray is a drug delivery system that delivers vitamins directly into the bloodstream through the mucous membranes under the tongue, bypassing the gastrointestinal tract and liver metabolism for rapid and efficient absorption. For instance, Vestige Marketing introduced Absorvit in October 2022, a sublingual vitamin spray that offers swift absorption and rapid results, providing 3-10 times greater absorption than traditional oral methods. It contains upgraded forms and precise doses of essential vitamins, including B12, C, D, and multivitamins, ensuring optimal nutrient delivery for improved wellness.

In January 2024, XOMA Corporation acquired DSUVIA from Talphera, Inc. for $8 million, aiming to capitalize on revenue from DSUVIA, a sufentanil sublingual tablet, while collaborating with Talphera and leveraging potential milestones from Alora Pharmaceuticals in the development of oral transmucosal drugs. Talphera Inc. is a pharmaceutical company involved in oral transmucosal drug development.

Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.

North America was the largest region in the oral transmucosal drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral transmucosal drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral transmucosal drugs market consists of sales of buccal patches, sublingual tablets, lozenges, and oral transmucosal powders. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Transmucosal Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral transmucosal drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral transmucosal drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral transmucosal drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets; Films; Liquid And Spray; Other Product Types
• 2) By Indication: Opioid Dependence; Nausea And Vomiting; Erectile Dysfunction; Neurological Disorders; Other Indications
• 3) By Route Of Administration: Sublingual Mucosa; Buccal Mucosa; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Tablets: Buccal Tablets; Sublingual Tablets; Effervescent Tablets
• 2) By Films: Buccal Films; Sublingual Films; Mucoadhesive Films
• 3) By Liquid And Spray: Sublingual Liquid Solutions; Oral Sprays (Pain Relief, Sleep Aids); Mucosal Gels
• 4) By Other Product Types: Lozenges; Pastilles; Chewing Gums
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi-Aventis LLC; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Transmucosal Drugs Market Characteristics

3. Oral Transmucosal Drugs Market Trends And Strategies

4. Oral Transmucosal Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oral Transmucosal Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Transmucosal Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Transmucosal Drugs Market Growth Rate Analysis
• 5.4. Global Oral Transmucosal Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Transmucosal Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Transmucosal Drugs Total Addressable Market (TAM)

6. Oral Transmucosal Drugs Market Segmentation

• 6.1. Global Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Films
• Liquid And Spray
• Other Product Types
• 6.2. Global Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Opioid Dependence
• Nausea And Vomiting
• Erectile Dysfunction
• Neurological Disorders
• Other Indications
• 6.3. Global Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sublingual Mucosa
• Buccal Mucosa
• Other Routes Of Administration
• 6.4. Global Oral Transmucosal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Oral Transmucosal Drugs Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Buccal Tablets
• Sublingual Tablets
• Effervescent Tablets
• 6.6. Global Oral Transmucosal Drugs Market, Sub-Segmentation Of Films, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Buccal Films
• Sublingual Films
• Mucoadhesive Films
• 6.7. Global Oral Transmucosal Drugs Market, Sub-Segmentation Of Liquid And Spray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sublingual Liquid Solutions
• Oral Sprays (Pain Relief, Sleep Aids)
• Mucosal Gels
• 6.8. Global Oral Transmucosal Drugs Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lozenges
• Pastilles
• Chewing Gums

7. Oral Transmucosal Drugs Market Regional And Country Analysis

• 7.1. Global Oral Transmucosal Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Transmucosal Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Transmucosal Drugs Market

• 8.1. Asia-Pacific Oral Transmucosal Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Transmucosal Drugs Market

• 9.1. China Oral Transmucosal Drugs Market Overview
• 9.2. China Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Transmucosal Drugs Market

• 10.1. India Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Transmucosal Drugs Market

• 11.1. Japan Oral Transmucosal Drugs Market Overview
• 11.2. Japan Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Transmucosal Drugs Market

• 12.1. Australia Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Transmucosal Drugs Market

• 13.1. Indonesia Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Transmucosal Drugs Market

• 14.1. South Korea Oral Transmucosal Drugs Market Overview
• 14.2. South Korea Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Transmucosal Drugs Market

• 15.1. Western Europe Oral Transmucosal Drugs Market Overview
• 15.2. Western Europe Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Transmucosal Drugs Market

• 16.1. UK Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Transmucosal Drugs Market

• 17.1. Germany Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Transmucosal Drugs Market

• 18.1. France Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Transmucosal Drugs Market

• 19.1. Italy Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Transmucosal Drugs Market

• 20.1. Spain Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Transmucosal Drugs Market

• 21.1. Eastern Europe Oral Transmucosal Drugs Market Overview
• 21.2. Eastern Europe Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Transmucosal Drugs Market

• 22.1. Russia Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Transmucosal Drugs Market

• 23.1. North America Oral Transmucosal Drugs Market Overview
• 23.2. North America Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Transmucosal Drugs Market

• 24.1. USA Oral Transmucosal Drugs Market Overview
• 24.2. USA Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Transmucosal Drugs Market

• 25.1. Canada Oral Transmucosal Drugs Market Overview
• 25.2. Canada Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Transmucosal Drugs Market

• 26.1. South America Oral Transmucosal Drugs Market Overview
• 26.2. South America Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Transmucosal Drugs Market

• 27.1. Brazil Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Transmucosal Drugs Market

• 28.1. Middle East Oral Transmucosal Drugs Market Overview
• 28.2. Middle East Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Transmucosal Drugs Market

• 29.1. Africa Oral Transmucosal Drugs Market Overview
• 29.2. Africa Oral Transmucosal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Transmucosal Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Transmucosal Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Transmucosal Drugs Market Competitive Landscape And Company Profiles

• 30.1. Oral Transmucosal Drugs Market Competitive Landscape
• 30.2. Oral Transmucosal Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Oral Transmucosal Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly & Company Ltd.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Biogen Inc.
• 31.9. Actavis Pharma Inc.
• 31.10. Sun Pharmaceutical Industries Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Endo Pharmaceuticals Inc.
• 31.13. Lupin Limited
• 31.14. Zydus Lifesciences Limited
• 31.15. Mallinckrodt Pharmaceuticals Plc

32. Global Oral Transmucosal Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Transmucosal Drugs Market

34. Recent Developments In The Oral Transmucosal Drugs Market

35. Oral Transmucosal Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Oral Transmucosal Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Transmucosal Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Transmucosal Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer